Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

22.23 +0.33 (+1.51%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 31, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

March 25, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

March 24, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

March 19, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

March 16, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

February 27, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

February 26, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

February 25, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

February 24, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

February 11, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

February 04, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

January 26, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

January 23, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

January 12, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease

January 07, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 31, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

December 11, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

November 25, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

November 24, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information

November 14, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

November 03, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

October 27, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

October 03, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 30, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth

September 15, 2025

Via Investor Brand Network

Topics Artificial Intelligence Intellectual Property

Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth

September 15, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NASDAQ:SRPT),(NASDAQ:AUTL),(NASDAQ:ARCT) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence Intellectual Property

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

September 05, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action

August 29, 2025

From Robbins LLP

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.